XELIRI regimen plus continuous treatment with bevacizumab is well-tolerated and effective in metastatic colorectal cancer patients in a second-line setting involving the sequential administration of XELOX and XELIRI

The aim of the present study was to present a retrospective review of 42 metastatic colorectal cancer (mCRC) patients treated using the XELIRI regimen as second-line chemotherapy during the period between 2010 and 2012. Patients were treated with capecitabine, 1,600 (≥65 years) or 2,000 mg/m(2) (<...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: SUZUKI, KOICHI, TAKAHARU, KATO, MUTO, YUTA, ICHIDA, KOSUKE, FUKUI, TARO, TAKAYAMA, YUJI, TSUJINAKA, SHINGO, SASAKI, JUNICHI, HORIE, HISANAGA, KAWAMURA, YUTAKA J., KONISHI, FUMIO, RIKIYAMA, TOSHIKI
Médium: Artigo
Jazyk:Inglês
Vydáno: D.A. Spandidos 2014
Témata:
Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4106724/
https://ncbi.nlm.nih.gov/pubmed/25054053
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2014.306
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky